2012
Glypican‐3 as a Potential Therapeutic Target for Hepatocellular Carcinoma Immunotherapy
Trinh T, Liu C. Glypican‐3 as a Potential Therapeutic Target for Hepatocellular Carcinoma Immunotherapy. The FASEB Journal 2012, 26: 405.1-405.1. DOI: 10.1096/fasebj.26.1_supplement.405.1.Peer-Reviewed Original ResearchHCC cell linesDifferent HCC cell linesGlypican-3Hepatocellular carcinomaTherapeutic targetCell linesNon-tumor liver tissuesHepatocellular Carcinoma ImmunotherapyCell proliferationNovel therapeutic targetPotential therapeutic targetCancer cell proliferationInhibited cell proliferationDose-dependent mannerAnti-GPC3 antibodiesHuman HCC tissuesNormal primary hepatocytesHCC immunotherapyCell surface heparinGPC3 expressionHCC tissuesLiver tissueImmunotherapyWestern blotHuman tumors
2009
Hepatocellular Carcinoma Immunopathogenesis: Clinical Evidence for Global T Cell Defects and an Immunomodulatory Role for Soluble CD25 (sCD25)
Cabrera R, Ararat M, Cao M, Xu Y, Wasserfall C, Atkinson M, Liu C, Nelson D. Hepatocellular Carcinoma Immunopathogenesis: Clinical Evidence for Global T Cell Defects and an Immunomodulatory Role for Soluble CD25 (sCD25). Digestive Diseases And Sciences 2009, 55: 484-495. PMID: 19714465, PMCID: PMC3161029, DOI: 10.1007/s10620-009-0955-5.Peer-Reviewed Original ResearchConceptsT cell responsesHCC patientsHepatocellular carcinomaCell responsesTumor burdenImpaired T cell responsesLower IFN-γ productionEffector T cell responsesIL-2 receptor alpha chainATP production assaysLevels of sCD25Tolerogenic tumor environmentIFN-γ ELISPOTEffector T cellsT cell immunityT cell reactivityIFN-γ productionIL-2 supplementationT cell defectsDose-dependent mannerReceptor alpha chainIL-2 signalingSerum sCD25Soluble CD25Worse survival
2005
Critical Role for CCR1:CCL5 (RANTES) Receptor Ligand Interactions in Modulating Allogeneic T Cell Responses Following Bone Marrow Transplantation.
Choi S, Hildebrandt G, Silva I, Olkiewicz K, Chensue S, Liu C, Chaudhary M, Fisher J, Lane T, Cooke K. Critical Role for CCR1:CCL5 (RANTES) Receptor Ligand Interactions in Modulating Allogeneic T Cell Responses Following Bone Marrow Transplantation. Blood 2005, 106: 3107. DOI: 10.1182/blood.v106.11.3107.3107.Peer-Reviewed Original ResearchT cell responsesGVL effectAllo-SCTT cellsCell responsesChemokine receptorsAllogeneic T-cell responsesAllo-SCT recipientsDonor T-cell alloreactivityGVHD target tissuesSerum IFNγ levelsSeverity of GVHDTarget tissuesLeukemia-free survivalClinical scoring systemBone marrow transplantationT cell expansionT-cell alloreactivityBone marrow inoculumHost target tissuesActivated T cellsP815 tumor cellsDose-dependent mannerHigher tumor dosesAcute graftNovel type I interferon IL-28A suppresses hepatitis C viral RNA replication
Zhu H, Butera M, Nelson D, Liu C. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virology Journal 2005, 2: 80. PMID: 16146571, PMCID: PMC1232870, DOI: 10.1186/1743-422x-2-80.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntiviral AgentsBase SequenceCell LineGenes, MHC Class IHepacivirusHepatitis CHumansInterferon Regulatory Factor-1Interferon Type IInterferon-alphaInterferon-Stimulated Gene Factor 3Interleukin-10InterleukinsJanus KinasesMolecular Sequence DataRNA, ViralSignal TransductionSTAT Transcription FactorsVirus ReplicationConceptsInterferon-stimulated genesIL-28AAntiviral activityAntiviral efficacyHuman hepatoma cellsSide effectsChronic hepatitis C viral infectionHepatitis C viral infectionViral RNA replicationAntiviral response ratesHCV subgenomic RNA replicationIFNα-based therapyGenotype 1 infectionHCV chronic infectionC viral infectionIL-10 receptorIL-10 treatmentHLA class IType I IFNJAK-STATRNA replicationDose-dependent mannerHepatoma cellsExpression of ISGsUndesirable side effectsCyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation
Firpi R, Zhu H, Morelli G, Abdelmalek M, Soldevila‐Pico C, Machicao V, Cabrera R, Reed A, Liu C, Nelson D. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transplantation 2005, 12: 51-57. PMID: 16382464, DOI: 10.1002/lt.20532.Peer-Reviewed Original ResearchConceptsLiver transplant recipientsSustained virological responseVirological responseTransplant recipientsCombination of cyclosporineInterferon-based therapyCombination of interferonEffect of cyclosporineDose-dependent mannerAnti-viral potentialLiver transplantationHistologic diseaseImmunosuppressive agentsViral clearanceHerpes simplexC virusAntiviral effectCyclosporine inhibitsCyclosporineTherapyViral replicationAntiviral activityTacrolimusInterferonReplicon system